Aortic regurgitation occurs when blood leaks back into the left ventricle due to a leaky aortic valve. This is a type of valve disease in the heart. Aortic regurgitation can lead to some heart damage ...

SAN FRANCISCO -- Aortic valve regurgitation treated with the investigational JenaValve Trilogy appeared safe and effective in the ALIGN AR trial. The device met the safety benchmark, with a 26.7% rate ...

JenaValve has secured the FDA’s approval for its minimally invasive heart implant, making it the first to claim a U.S. green ...

The FDA approved the Trilogy Transcatheter Heart Valve System for the treatment of symptomatic severe aortic regurgitation, ...

Asymptomatic women with moderate-to-severe aortic regurgitation and preserved left ventricular (LV) function managed without surgery had lower survival rates than their male counterparts, although ...

WASHINGTON — A phase 3 randomized trial will soon begin for the first transcatheter aortic valve replacement (TAVR) device for the treatment of aortic valve regurgitation after promising results in a ...

This marks the first dedicated transcatheter heart valve approved for high-risk patients with symptomatic severe AR.

Add Yahoo as a preferred source to see more of our stories on Google. JenaValve has received premarket approval from the Food and Drug Administration for its transcatheter heart valve to treat ...

To the Editor: In their article, Mack et al. (Nov. 23 issue) 1 imply that transcatheter aortic-valve replacement (TAVR) provides results that are similar to those of surgical aortic-valve replacement ...

Please provide your email address to receive an email when new articles are posted on . A novel TAVR system was safe and effective for adults with severe aortic regurgitation who are not surgical ...

COPENHAGEN, Denmark—Among patients with severe aortic stenosis at low- or intermediate-risk for surgery who also have very calcified aortic valves, SAVR is associated with lower risks of all-cause ...